Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
luvometinib + anlotinib
- Development stage
- Unknown
- Lead developer
- Fosun Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Luvometinib + anlotinib is a combination therapy consisting of luvometinib (FCN-159), a potent and selective MEK1/2 inhibitor, and anlotinib, a multi-targeted tyrosine kinase inhibitor. Luvometinib targets the MAPK/ERK pathway, which is frequently dysregulated in KRAS-mutated cancers, by inhibiting the phosphorylation of ERK. Anlotinib suppresses tumor growth and angiogenesis by inhibiting multiple receptor tyrosine kinases, including VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit. This combination is being investigated by Fosun Pharma for the treatment of KRAS-mutated metastatic non-small cell lung cancer (NSCLC), aiming to provide synergistic anti-tumor activity by simultaneously blocking intracellular signaling and tumor vascularization.
- Other names
- FCN-159 + anlotinibluvometinib + AL3818FCN-159 + AL3818
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on luvometinib + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on luvometinib + anlotinib.